PI3K Pathway Activity and Response to First-Line Chemotherapy in Combination with Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
Vorkas, P. A.
Agelaki, S.
Poumpouridou, N.
Kroupis, C.
Mavroudis, D.
Stathopoulos, E.
Georgoulias, V
Liandou, E. S.
机构：
[1] Univ Athens, Sch Med, GR-11527 Athens, Greece
[2] Univ Gen Hosp Heraklion, Iraklion, Crete, Greece
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：599S / 599S
页数：1
相关论文
共 50 条
  • [31] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [32] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [33] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [34] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [35] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [36] Pharmacoeconomic analysis of a combination of capecitabine (X) with docetaxel (D) and trastuzumab (H) first-line in HER2-positive advanced or metastatic breast cancer
    Bonetti, A.
    Santoro, A.
    Cirrincione, A.
    Giuliani, G.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Phase II Study of a Triple Combination of Oral Vinorelbine, Capecitabine and Trastuzumab as First-line Treatment in HER2-positive Metastatic Breast Cancer
    Chan, Arlene
    Conte, Pier-Franco
    Petruzelka, Lubos
    Tubiana-Mathieu, Nicole
    Ganju, Vinod
    Llombart, Antonio
    Espie, Marc
    Majois, Francoise
    Gil, Miguel Gil
    Vaissiere, Nathalie
    Villanova, Gustavo
    ANTICANCER RESEARCH, 2013, 33 (06) : 2657 - 2664
  • [38] Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
    Leung, John Hang
    Tai, Yun-sheng
    Wang, Shyh-Yau
    Fion, Hei-Tung Yip
    Tsung-chin, Ho
    Chan, Agnes Lf
    BREAST, 2022, 65 : 91 - 97
  • [39] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
12345